Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.50 |
| ▸ | HRH2 | P25021 | 4/20 | 0.49 |
| ▸ | HRH1 | P35367 | 4/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976172 | 0.96 | HRH3 (0.57) | HRH3HRH2HRH1MEN1KMT2A | |
| SCHEMBL1730298 | 0.88 | TBXAS1 (0.46) | KCNA5HRH1LTA4HMEN1KMT2A | |
| SCHEMBL1730790 | 0.87 | KCNA5 (0.58) | HRH3KCNA5HRH2HRH1LTA4H | |
| SCHEMBL1730302 | 0.87 | LTA4H (0.63) | HRH3KCNA5HRH2HRH1LTA4H | |
| SCHEMBL4178466 | 0.85 | HRH1 (0.50) | HRH3HRH2HRH1MEN1KMT2A | |
| SCHEMBL4179888 | 0.84 | HRH3 (0.60) | HRH3KCNA5HRH2HRH1MEN1 | |
| SCHEMBL1730947 | 0.83 | HRH3 (0.69) | HRH3HRH2HRH1LTA4HMEN1 | |
| SCHEMBL4173098 | 0.82 | LTA4H (0.59) | HRH3LTA4HKDM1AKCNH2 | |
| SCHEMBL1714312 | 0.82 | HRH3 (0.71) | HRH3KCNA5HRH2HRH1KCNH2 | |
| SCHEMBL14393462 | 0.80 | HRH3 (0.57) | HRH3HRH2HRH1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221607-A1 | Piperazine Derivatives | M'S SCIENCE CORPORATION (JP) | 2009-09-03 | — | — | US | claimed |
| EP-1988902-B1 | PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20090221607-A1 | Piperazine Derivatives | M'S SCIENCE CORPORATION (JP) | 2009-09-03 | — | — | US | disclosed |
| EP-1988902-A4 | PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2009-05-06 | — | — | EP | disclosed |
| EP-1988902-A2 | PIPERAZINE DERIVATIVES | M's Science Corporation (JP) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007097871-A2 | PIPERAZINE DERIVATIVES | M'S SCIENCE CORPORATION (JP) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221607-A1 | Piperazine Derivatives | SIGMAR1, OPRL1, OPRK1 | HRH3 295/4885KCNA5 555/4885HRH2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.